Taming the transplantation troll by targeting terminase

New England Journal of Medicine

Volumn 370, Issue 19, 2014, Pages 1844-1846

  Griffiths, Paul D ^a   Emery, Vincent C ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; LETERMOVIR; TERMINASE; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA; VIRUS ENZYME;

CYTOMEGALOVIRUS INFECTION; DNA CLEAVAGE; DNA DETERMINATION; DRUG SAFETY; EDITORIAL; HUMAN; INFECTION CONTROL; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN TARGETING; STEM CELL TRANSPLANTATION; TREATMENT INDICATION; VIREMIA; VIRUS DETECTION; VIRUS MORPHOLOGY;

ACETATES; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS; QUINAZOLINES;

EID: 84899821061     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1401567     Document Type: Editorial

References (10)

1. Balfour HH Jr. Cytomegalovirus: the troll of transplantation. Arch Intern Med 1979;139:279-80.
2. Marty FM, Boeckh M. Maribavir and human cytomegalovirus - what happened in the clinical trials and why might the drug have failed? Curr Opin Virol 2011;1:555-62.
3. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013;2:CD005133.
4. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013;96: 333-60.
5. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014;370:1781-9.
6. Newcomb WW, Juhas RM, Thomsen DR, et al. The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J Virol 2001;75:10923-32. (Pubitemid 33031559)
7. Brown JC, Newcomb WW. Herpesvirus capsid assembly: insights from structural analysis. Curr Opin Virol 2011;1:142-9.
8. Bogner E. Human cytomegalovirus terminase as a target for antiviral chemotherapy. Rev Med Virol 2002;12:115-27. (Pubitemid 34273046)
9. Fryer JF, WHO Expert Committee on Biological Standardization. Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. Geneva: World Health Organization, 2010. (Publication no. WHO/BS/10.2138.)
10. Kimberlin DW, Lin CY, Sánchez PJ, et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143:16-25. (Pubitemid 36928564)